Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial
Adjuvant S-1 after NAC-S showed promising efficacy with a manageable safety profile for patients with resectable ESCC and warrants further evaluation in larger studies.
Authors
- Eishi Baba
- Manabu Muto (ORCID: https://orcid.org/0000-0002-3127-8203)
- Shinji Hato
- Hideki Ishikawa (ORCID: https://orcid.org/0000-0001-5980-698X)
- Masahiro Tsuda (ORCID: https://orcid.org/0000-0001-6442-9250)
- Motoo Nomura (ORCID: https://orcid.org/0000-0002-5967-0610)
- Hisahiro Matsubara (ORCID: https://orcid.org/0000-0002-2335-4704)
- Toshifumi Yamaguchi (ORCID: https://orcid.org/0000-0003-1399-1918)
- Ken Kato (ORCID: https://orcid.org/0000-0002-1733-5072)
- Isao Oze (ORCID: https://orcid.org/0000-0002-0762-1147)
- Takako Yoshii
- Yuko Kitagawa (ORCID: https://orcid.org/0000-0002-0271-5670)
- Keisho Chìn (ORCID: https://orcid.org/0000-0002-2015-8185)
- Hidenori Mukaida
- Yasuhiro Tsubosa
Institutions
- Kyushu University (JP)
- Chiba University (JP)
- Keio University (JP)
- Kyoto University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Shizuoka Cancer Center (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Saitama Cancer Center (JP)
- Aichi Cancer Center (JP)
- Shikoku Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Kyoto University Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Japanese Foundation For Cancer Research (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1245/s10434-024-16325-2
- Citations
- 4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- Taiho Pharmaceutical